These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 25435314)

  • 1. Dopamine bioavailability in the mPFC modulates operant learning performance in rats: an experimental study with a computational interpretation.
    Rapanelli M; Frick LR; Miguelez Fernández AM; Zanutto BS
    Behav Brain Res; 2015 Mar; 280():92-100. PubMed ID: 25435314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral and central inhibitors of catechol-O-methyl transferase: effects on liver and brain COMT activity and L-DOPA metabolism.
    Brannan T; Prikhojan A; Yahr MD
    J Neural Transm (Vienna); 1997; 104(1):77-87. PubMed ID: 9085195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease.
    Li LS; Liu CZ; Xu JD; Zheng LF; Feng XY; Zhang Y; Zhu JX
    World J Gastroenterol; 2015 Mar; 21(12):3509-18. PubMed ID: 25834315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
    Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
    Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue and interspecies comparison of catechol-
    Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
    Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
    Detrait ER; Carr GV; Weinberger DR; Lamberty Y
    Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.
    Byers S; Buchler IP; DePasquale M; Rowley HL; Kulkarni RS; Pinder L; Kolobova A; Li C; Au V; Akuma D; Zhang G; Wei H; Cheetham SC; Barrow JC; Carr GV
    Psychopharmacology (Berl); 2020 Sep; 237(9):2695-2707. PubMed ID: 32474681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone.
    Nissinen E; Lindén IB; Schultz E; Pohto P
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Sep; 346(3):262-6. PubMed ID: 1407012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of extracellular dopamine in the medial prefrontal cortex of conscious mice analysed using selective enzyme and uptake inhibitors.
    Tammimaki A; Aonurm-Helm A; Kaenmaki M; Mannisto PT
    J Physiol Pharmacol; 2016 Apr; 67(2):301-9. PubMed ID: 27226189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different renal effects of two inhibitors of catechol-O-methylation in the rat: entacapone and CGP 28014.
    Hansell P; Odlind C; Männistö PT
    Acta Physiol Scand; 1998 Apr; 162(4):489-94. PubMed ID: 9597116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions.
    Laatikainen LM; Sharp T; Harrison PJ; Tunbridge EM
    PLoS One; 2013; 8(4):e61839. PubMed ID: 23613951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medial Prefrontal Cortical Dopamine Responses During Operant Self-Administration of Sweetened Ethanol.
    Doherty JM; Schier CJ; Vena AA; Dilly GA; Gonzales RA
    Alcohol Clin Exp Res; 2016 Aug; 40(8):1662-70. PubMed ID: 27435872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine in the prefrontal cortex regulates rats behavioral flexibility to changing reward value.
    Winter S; Dieckmann M; Schwabe K
    Behav Brain Res; 2009 Mar; 198(1):206-13. PubMed ID: 19041903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
    Forsberg MM; Huotari M; Savolainen J; Männistö PT
    Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A neurocomputational model of dopamine and prefrontal-striatal interactions during multicue category learning by Parkinson patients.
    Moustafa AA; Gluck MA
    J Cogn Neurosci; 2011 Jan; 23(1):151-67. PubMed ID: 20044893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forebrain D1 function and sensorimotor gating in rats: effects of D1 blockade, frontal lesions and dopamine denervation.
    Swerdlow NR; Shoemaker JM; Kuczenski R; Bongiovanni MJ; Neary AC; Tochen LS; Saint Marie RL
    Neurosci Lett; 2006 Jul; 402(1-2):40-5. PubMed ID: 16644125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
    Maltête D; Cottard AM; Mihout B; Costentin J
    Clin Neuropharmacol; 2011; 34(1):21-3. PubMed ID: 21164341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane bound catechol-O-methytransferase is the dominant isoform for dopamine metabolism in PC12 cells and rat brain.
    Su Y; DePasquale M; Liao G; Buchler I; Zhang G; Byers S; Carr GV; Barrow J; Wei H
    Eur J Pharmacol; 2021 Apr; 896():173909. PubMed ID: 33503461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
    Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
    J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.